Weekly Digest – April 2026 Weekly Digest – April 2026 14 April 2026: CrossBridge Bio enters an agreement to be acquired by Eli Lilly to advance next-generation dual-payload ADCs CrossBridge Bio, Inc. has entered into a definitive agreement to be […]
Weekly Digest – April 2026 Weekly Digest – April 2026 10 April 2026: 3B Pharmaceuticals and TetraKit Technologies announce strategic collaboration for joint radioligand therapy (RLT) development 3B Pharmaceuticals GmbH and TetraKit Technologies have entered into a strategic collaboration to […]
Weekly Digest – April 2026 Weekly Digest – April 2026 09 April 2026: The New Drug Application (NDA) for DB-1303/BNT323 for unresectable or metastatic HER2-positive adult breast cancer has been accepted by the NMPA DualityBio’s HER2 ADC DB-1303 (BNT323 / […]
Weekly Digest – April 2026 Weekly Digest – April 2026 07 April 2026: NextCure receives Fast Track Designation for SIM0505 (CDH6 ADC) in ovarian cancer NextCure has received FDA Fast Track Designation for its ADC SIM0505 for the treatment of […]
Weekly Digest – April 2026 Weekly Digest – April 2026 09 April 2026: Celltrion ADC drug candidate CT-P71 receives FDA Fast Track Designation for urothelial carcinoma Celltrion’s ADC candidate CT-P71 has received FDA Fast Track Designation for the treatment of […]
Weekly Digest – April 2026 Weekly Digest – April 2026 07 April 2026: Corbus Pharmaceuticals announces broad alignment with FDA on registration path for CRB-701 in second-line HNSCC and cervical cancer Corbus Pharmaceuticals has achieved broad alignment with the FDA […]
Weekly Digest – April 2026 Weekly Digest – April 2026 06 April 2026: Akari Therapeutics announces strategic partnership with WuXi XDC to advance development of its novel ADC payload targeting RNA splicing Akari Therapeutics has entered into a strategic partnership […]
Weekly Digest – April 2026 Weekly Digest – April 2026 08 April 2026: Sidewinder Therapeutics announces $137 million series B financing to advance precision bispecific ADCs into clinical development for cancer Sidewinder Therapeutics has secured $137 million in an oversubscribed […]
Weekly Digest – April 2026 Weekly Digest – April 2026 27 March 2026: ENHERTU followed by THP approved in China as the first and only HER2 directed ADC for the neoadjuvant treatment of HER2 positive breast cancer ENHERTU in combination […]
Weekly Digest – April 2026 Weekly Digest – April 2026 30 March 2026: Zymeworks receives U.S. FDA Fast Track Designation for ZW191, an FRα-targeting ADC Zymeworks’ FRα-targeting ADC, ZW191, has received FDA Fast Track designation for patients with advanced or […]
